EMA Panel Backs Adalimumab Biosimilar Amsparity EMA Panel Backs Adalimumab Biosimilar Amsparity

The CHMP has recommended approval of Pfizer ' s adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children.International Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news